Scarica l'app Stockscreener
2.24
0.00%
0.00
Dopo l'orario di chiusura:
2.22
-0.02
-0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.24
Aprire:
$2.26
Volume 24 ore:
11.55M
Relative Volume:
0.81
Capitalizzazione di mercato:
$810.55M
Reddito:
$241.53M
Utile/perdita netta:
$-389.92M
Rapporto P/E:
-1.8211
EPS:
-1.23
Flusso di cassa netto:
$-323.54M
1 W Prestazione:
+2.28%
1M Prestazione:
-2.61%
6M Prestazione:
-27.04%
1 anno Prestazione:
-76.09%
Intervallo 1D:
$2.20
$2.31
Intervallo di 1 settimana:
$2.04
$2.31
Portata 52W:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.24 | 767.13M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Why Iovance Biotherapeutics Inc. stock appeals to analysts2025 Performance Recap & AI Forecast Swing Trade Picks - newser.com
Why Iovance Biotherapeutics Inc. stock is favored by top institutionsIPO Watch & Reliable Entry Point Alerts - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
Identifying reversal signals in Iovance Biotherapeutics Inc.Earnings Summary Report & AI Driven Price Predictions - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraRecession Risk & Real-Time Market Trend Scan - newser.com
Using flow based indicators on Iovance Biotherapeutics Inc.July 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Iovance Biotherapeutics Inc. stock prediction for this weekEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - AOL.com
Signal strength of Iovance Biotherapeutics Inc. stock in tech scannersInsider Selling & Smart Allocation Stock Tips - newser.com
Using R and stats models for Iovance Biotherapeutics Inc. forecastingJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play (IOVA) - Seeking Alpha
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockGap Up & High Yield Stock Recommendations - newser.com
Real time breakdown of Iovance Biotherapeutics Inc. stock performanceJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potential - newser.com
Iovance Biotherapeutics (NASDAQ:IOVA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat
Iovance Biotherapeutics Inc Stock Analysis and ForecastIndustrial Stocks Review & Stay Ahead With Daily Market Discussions - earlytimes.in
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following Global Regulatory Push—Learn Why - Sahm
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance
Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com
Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm
How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):